drugset
drugset / Trial / NCT00319748

Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers

NCT00319748 ↗

Phase 2 Completed 15 enrolled Masonic Cancer Center, University of Minnesota Pfizer · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the anti-tumor activity of 852A when used to treat metastatic breast, ovarian, endometrial or cervical cancer not responding to standard treatment.

Timeline

Start
2006-04
Primary completion
2007-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject CPG-52852 Small molecule 0.6 mg/m2 Subcutaneous

Indications

breast cancer cervical cancer endometrial cancer ovarian cancer